AVTR

Avantor, Inc. AVTR

$11.07 -0.19 (-1.69%)

Extended · +1.65σ

+ Compare Open in Sniper

Price chart

Timeframe

Range

Loading…

Latest bar · AVTR

Momentum reads · latest daily bar

Last

$11.07

-0.19 (-1.69%)

Mkt cap

$7.6B

Healthcare

RSI(14)

64.7

neutral

Stochastic %K

83.2

overbought

MFI(14)

68.9

neutral

ADX(14)

38.5

trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

Quarter	Revenue	Net income	Op income	FCF	Net margin	Op margin
2026-03-31	$1.6B	$0.0B	$0.1B	$0.0B	2.7%	6.3%
2025-12-31	$1.7B	$0.1B	$0.1B	$0.1B	3.1%	7.9%
2025-09-30	$1.6B	$-0.7B	$0.1B	$0.2B	-43.8%	8.4%
2025-06-30	$1.7B	$0.1B	$0.1B	$0.1B	3.8%	7.7%
2025-03-31	$1.6B	$0.1B	$0.1B	$0.1B	4.1%	9.3%
2024-12-31	$nanB	$nanB	$nanB	$nanB	nan%	nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare AVTR vs peers

Line AVTR up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing AVTR NVDA× ABBV× AVGO×

Sector peers + LLY + UNH + JNJ + MRK + PFE + TMO

Popular + AAPL + MSFT + AMZN + GOOG + META + TSLA

Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Verdict

Weighted score 0-100 across 4 tickers · best in green

AVTR

score 49.5

3/5 inputs

Sentiment dominates at 98/100 offsetting zero quality, but extended zone at 1.65σ limits upside potential here.

quality 0momentum 50sentiment 98

NVDA

score 66.0

3/5 inputs

Perfect quality score of 100/100 carries this to rank one despite mediocre momentum dragging overall performance down.

quality 100momentum 39sentiment 68

ABBV

score 58.8

5/5 inputs

Momentum strength at 91/100 plus attractive 0.42 PEG ratio drive second place despite extended 1.46σ technical positioning.

value 50growth 50quality 38momentum 91sentiment 67

AVGO

score 9.9

3/5 inputs

Catastrophic insider selling at negative 43% crushes sentiment to zero, making this dead last despite pullback entry zone.

quality 2momentum 23sentiment 0

Metric	AVTR AVTR	NVDA NVDA	ABBV AbbVie Inc.	AVGO AVGO
Snapshot
Price	11.07	202.81	254.49	370.83
Day %↕	-1.69	-2.21	0.04	-0.97
1M %↕	15.67	-2.22	14.39	-1.56
3M %↕	34.02	2.25	21.77	-6.94
YTD %↕	-3.4	7.39	10.98	6.68
Market cap	—	—	449631125504.0	—
ADV ($)	—	—	1818746671.4276276	—
Beta	—	—	0.283	—
OdysseyHQ zone
Current zone	Extended	Neutral	Extended	Pullback
Dist 21-EMA %	7.17	-0.9	3.95	-3.79
Dist ATR (σ)	1.65	-0.25	1.46	-0.84
OdysseyHQ grade	C	—	—	—
Confluence↕	4	2	2	2
Valuation
P/E (ttm)↕	—	—	124.75001	—
P/E (fwd)↕	—	—	15.63166	—
P/S↕	—	—	7.1575656	—
EV/EBITDA↕	—	—	17.155	—
P/B↕	—	—	-67.55774	—
FCF yield↕	—	—	0.0463	—
PEG↕	—	—	0.42	—
Growth
Revenue yoy↕	—	—	0.124	—
EPS yoy↕	—	—	-0.462	—
FCF yoy↕	—	—	—	—
Revenue trend 8Q
Quality
Gross margin↕	—	—	0.72026	—
Operating margin↕	—	—	0.32156	—
Net margin↕	—	—	0.05786	—
ROE↕	—	—	—	—
ROA↕	—	—	0.10032	—
Debt / Equity↕	—	—	—	—
Interest cov.↕	-1.6	547.14	3.28	8.08
Technicals
RSI(14)	64.7	48.2	64.3	43.8
MACD signal	bull	bull	neutral	neutral
vs 50-DMA	18.58	-3.38	11.56	-7.97
vs 200-DMA	7.43	5.41	13.87	1.98
vs 52w high	-30.51	-14.26	-2.73	-25.08
HV-30	48.8	41.6	34.6	66.2
Sentiment
Analyst rec↕	—	—	1.74194	—
Target upside↕	—	—	4.75	—
Insider buy-sell 90d↕	12	-5	13	-43
Risk
Short interest↕	—	—	1.38	—
Days to cover↕	—	—	2.52	—
Next earnings	—	—	2026-07-31	—

AVTR

$11.07

-1.69%

Snapshot

Price 11.07

Day % -1.69

1M % 15.67

3M % 34.02

YTD % -3.4

Market cap —

ADV ($) —

Beta —

OdysseyHQ zone

Current zone Extended

Dist 21-EMA % 7.17

Dist ATR (σ) 1.65

OdysseyHQ grade C

Confluence 4

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA —

P/B —

FCF yield —

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin —

Operating margin —

Net margin —

ROE —

ROA —

Debt / Equity —

Interest cov. -1.6

Technicals

RSI(14) 64.7

MACD signal bull

vs 50-DMA 18.58

vs 200-DMA 7.43

vs 52w high -30.51

HV-30 48.8

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d 12

Risk

Short interest —

Days to cover —

Next earnings —

Full AVTR dashboard →

NVDA

$202.81

-2.21%

Snapshot

Price 202.81

Day % -2.21

1M % -2.22

3M % 2.25

YTD % 7.39

Market cap —

ADV ($) —

Beta —

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % -0.9

Dist ATR (σ) -0.25

OdysseyHQ grade —

Confluence 2

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA —

P/B —

FCF yield —

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin —

Operating margin —

Net margin —

ROE —

ROA —

Debt / Equity —

Interest cov. 547.14

Technicals

RSI(14) 48.2

MACD signal bull

vs 50-DMA -3.38

vs 200-DMA 5.41

vs 52w high -14.26

HV-30 41.6

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d -5

Risk

Short interest —

Days to cover —

Next earnings —

Full NVDA dashboard →

ABBV

AbbVie Inc.

$254.49

+0.04%

Snapshot

Price 254.49

Day % 0.04

1M % 14.39

3M % 21.77

YTD % 10.98

Market cap 449631125504.0

ADV ($) 1818746671.4276276

Beta 0.283

OdysseyHQ zone

Current zone Extended

Dist 21-EMA % 3.95

Dist ATR (σ) 1.46

OdysseyHQ grade —

Confluence 2

Valuation

P/E (ttm) 124.75001

P/E (fwd) 15.63166

P/S 7.1575656

EV/EBITDA 17.155

P/B -67.55774

FCF yield 0.0463

PEG 0.42

Growth

Revenue yoy 0.124

EPS yoy -0.462

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.72026

Operating margin 0.32156

Net margin 0.05786

ROE —

ROA 0.10032

Debt / Equity —

Interest cov. 3.28

Technicals

RSI(14) 64.3

MACD signal neutral

vs 50-DMA 11.56

vs 200-DMA 13.87

vs 52w high -2.73

HV-30 34.6

Sentiment

Analyst rec 1.74194

Target upside 4.75

Insider buy-sell 90d 13

Risk

Short interest 1.38

Days to cover 2.52

Next earnings 2026-07-31

Full ABBV dashboard →

AVGO

$370.83

-0.97%

Snapshot

Price 370.83

Day % -0.97

1M % -1.56

3M % -6.94

YTD % 6.68

Market cap —

ADV ($) —

Beta —

OdysseyHQ zone

Current zone Pullback

Dist 21-EMA % -3.79

Dist ATR (σ) -0.84

OdysseyHQ grade —

Confluence 2

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA —

P/B —

FCF yield —

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin —

Operating margin —

Net margin —

ROE —

ROA —

Debt / Equity —

Interest cov. 8.08

Technicals

RSI(14) 43.8

MACD signal neutral

vs 50-DMA -7.97

vs 200-DMA 1.98

vs 52w high -25.08

HV-30 66.2

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d -43

Risk

Short interest —

Days to cover —

Next earnings —

Full AVGO dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

Date	EPS actual	EPS est	Surprise	Next-day
2026-04-29	0.17	0.16	+8.2%	+3.2%
2026-02-11	0.22	0.22	+1.5%	-5.2%
2025-10-29	0.22	0.23	-2.3%	-4.6%
2025-08-01	0.24	0.25	-2.9%	-0.5%
2025-04-25	0.23	0.23	-0.7%	-3.4%
2025-02-07	0.27	0.26	+4.5%	-0.8%
2024-10-25	0.26	0.25	+2.1%	+0.9%
2024-07-26	0.25	0.23	+7.7%	+2.5%
2024-04-26	0.22	0.20	+9.6%	+0.6%
2024-02-14	0.25	0.22	+12.1%	-1.4%
2023-10-27	0.25	0.25	-0.3%	-3.8%
2023-07-28	0.28	0.29	-4.4%	-3.3%
2023-04-28	0.29	0.29	+1.6%	+3.9%
2023-02-03	0.32	0.30	+6.0%	+1.6%
2022-10-28	0.34	0.33	+3.0%	+4.9%
2022-07-28	0.37	0.38	-1.5%	-10.2%
2022-04-28	0.38	0.36	+7.0%	+7.0%
2022-02-03	0.36	0.33	+7.8%	-1.7%
2021-10-28	0.35	0.32	+9.6%	+5.4%
2021-07-29	0.35	0.31	+13.5%	+0.9%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅	Mkt cap ⇅	P/E ⇅	Fwd P/E ⇅	P/S ⇅	EV/EBITDA ⇅	P/B ⇅	Gross M ⇅	Rev gr ⇅	EPS gr ⇅	FCF yld ⇅
AVTR ★	$8B	—	13.0	1.2	11.7	1.3	32.1%	0.0%	-33.3%	6.47%
LLY	$1,051B	41.8	26.3	14.6	30.1	33.8	82.8%	55.5%	169.9%	0.87%
UNH	$387B	32.1	19.2	0.9	17.7	4.0	19.5%	0.4%	61.5%	5.88%
JNJ	$609B	29.3	19.7	6.2	18.4	7.5	68.1%	6.6%	-1.0%	—
MRK	$315B	36.0	13.2	4.8	12.1	6.9	76.7%	4.9%	—	4.46%
ABBV	$450B	124.8	15.6	7.2	17.2	-67.6	72.0%	12.4%	-46.2%	4.63%
PFE	$143B	19.1	8.8	2.3	7.6	1.6	74.8%	5.4%	-10.1%	8.67%
TMO	—	29.3	—	—	—	—	—	6.2%	—	2.78%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 54.73%

Holder	Shares	% out
Dodge & Cox Inc.	119,648,329	17.52%
Blackrock Inc.	65,703,554	9.62%
Vanguard Portfolio Management LLC	31,275,847	4.58%
Vanguard Capital Management LLC	30,606,112	4.48%
Wellington Management Group, LLP	24,224,156	3.55%
Greenhaven Associates, Inc.	22,593,838	3.31%
Barrow, Hanley Mewhinney & Strauss,	22,358,399	3.27%
State Street Corporation	20,721,079	3.03%
Engine Capital Management, LP	19,780,830	2.90%
Dimensional Fund Advisors LP	16,894,649	2.47%

Insider activity · 90d

12 buys / 0 sells · ratio 12.0 · Finnhub

Walker Corey F 384,535 @ $9.58
LUCIER GREGORY T BUY 60,000 @ $8.32
Murthy Mala BUY 69,479
Dingemans Simon BUY 31,495
Makin Louise BUY 47,140
SEVERINO MICHAEL BUY 85,821
Massaro Joseph R BUY 77,408
LUCIER GREGORY T BUY 34,006
SUMME GREGORY L BUY 83,381
MEHRA SANJEEV K BUY 33,376

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low

$7.0

Mean

$10.4375

High

$19.0

Analysts

Recommendation distribution · period 2026-07-01

Revision trend (2026-04-01 → 2026-07-01): net -3 → -3 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

Form	Filed	Description	Action
8-K	2026-07-17	8-K	view ·
4	2026-06-22	FORM 4	view ·
8-K	2026-05-12	8-K	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-11	FORM 4	view ·
4	2026-05-05	FORM 4	view ·
4	2026-05-05	FORM 4	view ·
10-Q	2026-04-29	10-Q	view ·
8-K	2026-04-29	8-K	view ·
8-K	2026-04-23	8-K	view ·
4	2026-04-06	FORM 4	view ·
8-K	2026-04-01	8-K	view ·
DEF 14A	2026-03-27	DEFINITIVE PROXY STATEMENT	view ·
4	2026-03-11	FORM 4	view ·
4	2026-02-25	FORM 4	view ·
4	2026-02-25	FORM 4	view ·
4	2026-02-25	FORM 4	view ·
4	2026-02-25	FORM 4	view ·
4	2026-02-25	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-23	FORM 4	view ·
4	2026-02-12	FORM 4	view ·
8-K	2026-02-11	8-K	view ·
10-K	2026-02-11	10-K	view ·
4	2026-01-12	FORM 4	view ·
8-K	2025-12-18	8-K	view ·
4	2025-12-09	FORM 4	view ·
8-K	2025-12-04	8-K	view ·
4	2025-11-17	FORM 4	view ·
4	2025-11-12	FORM 4	view ·
8-K	2025-11-10	8-K	view ·
4	2025-10-31	FORM 4	view ·
10-Q	2025-10-29	10-Q	view ·
8-K	2025-10-29	8-K	view ·
8-K	2025-10-14	8-K	view ·
8-K	2025-10-14	8-K	view ·
4	2025-10-07	FORM 4	view ·
4	2025-10-03	FORM 4	view ·
8-K	2025-10-03	8-K	view ·
4	2025-08-22	FORM 4	view ·
4	2025-08-21	FORM 4	view ·
4	2025-08-15	FORM 4	view ·
8-K	2025-08-13	8-K	view ·
4	2025-08-12	FORM 4	view ·
4	2025-08-06	FORM 4	view ·
4	2025-08-04	FORM 4	view ·
10-Q	2025-08-01	10-Q	view ·

About AVTR

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreacto…

Options picks · AVTR

ITM + OTM ideas from the latest scan

Loading…

Congress trades · AVTR

STOCK Act disclosures

Loading…

SEC filings & insiders · AVTR

EDGAR · live

Loading…

Holders · AVTR

Institutions & insider activity

Loading…

Avantor, Inc. AVTR

Price chart

Latest bar · AVTR

Financial overlay · last 12 quarters

Compare AVTR vs peers

Earnings replay · last 20 reports

Peer comparison · Healthcare

Ownership

Top institutional holders

Insider activity · 90d

Analyst estimates

SEC filings

About AVTR

Options picks · AVTR

Congress trades · AVTR

SEC filings & insiders · AVTR

Holders · AVTR

Filing summary